The FDA Just Approved This Company’s Alzheimer’s Treatment

finviz dynamic chart for  BIIB

Biogen (BIIB) is an American multinational biotechnology company that specializes in developing treatments for neurological diseases.

And similar to Novo Nordisk, BIIB recently released a groundbreaking drug that could fundamentally alter how medical professionals and families tackle Alzheimer’s moving forward. 

After years of studies, the firm's Alzheimer’s treatment Aduhelm showed that it could effectively slow the cognitive decline of the neurological disease by disrupting the development of amyloid beta plaque in patients.  

As a result, the U.S. Food and Drug Administration (FDA) approved its first Alzheimer’s treatment in over 20 years… And may even be the first truly “effective” therapy to slow Alzheimer’s progression.

This has many investors watching the company forecasting the drug could see sales of $63 million in 2021 alone.

Next year, Wall Street noted that number could surge to $603 million. And by 2023, they could rise above $1.6 billion… potentially surging much higher in the decade ahead.

“IMPERIUM:” The No. 1 Investment of the 2020s

Sponsored

Could this odd-looking machine really be the most transformative innovation in history?

Experts are screaming: “YES”! 

Elon Musk calls it “amazing…” 

A former Apple CEO says: “[It will] have a far bigger impact on humanity than the Internet.” 

While a Harvard Ph.D. says it could “[surpass] the space, atomic, and electronic revolutions in its significance.” 

It’s a technology I call “Imperium.” And it’s about to spark the biggest investment mega trend in history … with one small Silicon Valley company at the center of it all.   

To get all the details, click here now…

EV Play No One's Talking About

This company is a sneaky EV play that no one’s talking about. They’re producing the “oil” of electric vehicles and could hand big returns to the first movers.

Enter your email address to receive this company’s name and ticker symbol for free.


Free Bonus E-Book: The Second Wave Why popular tech stocks could be in store for a 92% meltdown and the #1 investment billionaires are turning to now... from Morning Bullets. Privacy Policy

By submitting your email address, you give Stock Market Junkie permission to 1. deliver the report or research you're requesting to your email inbox, 2. send free ongoing updates via our independent financial email newsletter, and 3. share carefully selected marketing offers for product and services we think will interest you. Your privacy and security are paramount to us. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

$30 Stock Freaking Out Billionaires

This stock is an industry leader in a robotics technology that is freaking out billionaires (trading for just $30).

Enter your email address to receive this company’s name and ticker symbol for free.


Free Bonus E-Book: The Second Wave Why popular tech stocks could be in store for a 92% meltdown and the #1 investment billionaires are turning to now... from Morning Bullets. Privacy Policy

By submitting your email address, you give Stock Market Junkie permission to 1. deliver the report or research you're requesting to your email inbox, 2. send free ongoing updates via our independent financial email newsletter, and 3. share carefully selected marketing offers for product and services we think will interest you. Your privacy and security are paramount to us. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

The Best TaaS Stock Right Now

This company is set to corner the market in a self-driving technology that  could fundamentally change our entire society – much like the internet did.

Enter your email address to receive this company’s name and ticker symbol for free.


Free Bonus E-Book: The Second Wave Why popular tech stocks could be in store for a 92% meltdown and the #1 investment billionaires are turning to now... from Morning Bullets. Privacy Policy

By submitting your email address, you give Stock Market Junkie permission to 1. deliver the report or research you're requesting to your email inbox, 2. send free ongoing updates via our independent financial email newsletter, and 3. share carefully selected marketing offers for product and services we think will interest you. Your privacy and security are paramount to us. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

Up to 20,000 IPOs All in One Day

A radical $2.1 quadrillion shift is coming to the financial markets.

Some are calling it G.T.E. and Mark Cuban, Elon Musk, Richard Branson, and even banks like J.P. Morgan are invested in the tech behind it.

Just $25 could get you in alongside these billionaires. 

Enter your email address to receive the video that reveals it all.


Free Bonus E-Book: The Second Wave Why popular tech stocks could be in store for a 92% meltdown and the #1 investment billionaires are turning to now... from Morning Bullets. Privacy Policy

By submitting your email address, you give Stock Market Junkie permission to 1. deliver the report or research you're requesting to your email inbox, 2. send free ongoing updates via our independent financial email newsletter, and 3. share carefully selected marketing offers for product and services we think will interest you. Your privacy and security are paramount to us. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

$2 Biotech Stock

Steve Cohen, the billionaire stock picker known for running one of the most successful hedge funds ever, has poured millions into the first stock, and it’s trading for only $2.

Enter your email address to receive this company’s name and ticker symbol for free.


Free Bonus E-Book: The Second Wave Why popular tech stocks could be in store for a 92% meltdown and the #1 investment billionaires are turning to now... from Morning Bullets. Privacy Policy

By submitting your email address, you give Stock Market Junkie permission to 1. deliver the report or research you're requesting to your email inbox, 2. send free ongoing updates via our independent financial email newsletter, and 3. share carefully selected marketing offers for product and services we think will interest you. Your privacy and security are paramount to us. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works